Work

XPO1 as a key regulator in small cell lung cancer: mechanisms, biomarkers, and therapeutic implications

Year: 2025

Type: article

Abstract: Small cell lung cancer (SCLC) is a highly aggressive malignancy with limited treatment options. Despite advances in immunotherapy, response rates remain low, and the efficacy of current molecular subtyping[1][1],[2][2] is insufficient to predict therapeutic outcomes[3][3],[4][4]. A recently

Source: Cancer Biology and Medicine

DOI: 10.20892/j.issn.2095-3941.2025.0215

Authors: Tingting Qin, Jingya Wang, Dingzhi Huang

Institutions: Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University

Language: English

Topic: Lung Cancer Research Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,500